| Literature DB >> 34454427 |
Gustav Mattsson1, Marita Wallhagen2, Peter Magnusson3,4.
Abstract
BACKGROUND: Self-reported health status as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ) in patients with primary prevention implantable cardioverter defibrillators (ICDs) has mainly been reported from randomized trials. However, these studies are often limited to short follow-up and are subject to selection bias. The aim of this study was to assess KCCQ-12 in patients with primary prevention ICD due to either ischemic or nonischemic heart failure.Entities:
Keywords: Cardiomyopathy; Heart failure; Implantable cardioverter defibrillator; Kansas City Cardiomyopathy Questionnaire; Quality of life
Mesh:
Year: 2021 PMID: 34454427 PMCID: PMC8403422 DOI: 10.1186/s12872-021-02218-9
Source DB: PubMed Journal: BMC Cardiovasc Disord ISSN: 1471-2261 Impact factor: 2.298
Fig. 1Flow-chart depicting the process for deriving the final sample for analysis
Characteristics at ICD implant of the 118 patients analyzed regarding KCCQ-12
| n (%) | |
|---|---|
| Patients | 118 |
| Mean age at implant (years) | 65.0 ± 10.4 |
| Mean age at KCCQ (years) | 70.9 ± 9.8 |
| Females | 20 (16.9) |
| Ischemic etiology | 69 (58.5) |
| Device type | |
| ICD-VR | 16 (13.6) |
| ICD-DR | 45 (38.1) |
| CRT-D | 57 (48.3) |
| Hypertension | 54 (45.8) |
| Diabetes mellitus | 27 (22.9) |
| Renal failure* | 16 (13.6) |
| Atrial fibrillation | 35 (29.7) |
| Beta-blockers | 106 (89.8) |
| ACE-i/ARB | 111 (94.1) |
| MRA | 75 (63.6) |
Data presented as frequencies (percentage in parenthesis)
ACE-i angiotensin converting enzyme inhibitor, ARB angiotensin receptor blockers, CRT-D cardiac resynchronization therapy defibrillator, ICD-DR dual lead implantable cardioverter defibrillator, ICD-VR single lead implantable cardioverter defibrillator, KCCQ-12 12-item Kansas City Cardiomyopathy Questionnaire, MRA mineralcorticoid receptor antagonists
*Defined as S-Creatinine ≥ 130 μmol/L
Mean score of the KCCQ-12 in 118 patients with primary prevention ICD due to heart failure
| KCCQ-12 | All | Ischemic HF | Nonischemic HF | Ischemic versus nonischemic HF |
|---|---|---|---|---|
| Physical limitation | 68.0 ± 26.4 | 64.6 ± 26.2 | 72.8 ± 26.1 | 0.062 |
| Symptom frequency | 78.6 ± 21.1 | 77.2 ± 21.5 | 80.6 ± 20.5 | 0.305 |
| Quality of life | 69.7 ± 25.7 | 68.8 ± 25.7 | 70.9 ± 25.8 | 0.582 |
| Social limitation | 71.6 ± 27.0 | 68.8 ± 27.1 | 75.6 ± 26.7 | 0.144 |
| Overall summary score | 71.5 ± 22.4 | 69.5 ± 23.1 | 74.4 ± 21.3 | 0.195 |
Statistically significant p-values are given in bold
Comparisons are made between ischemic versus nonischemic HF and VR/DR versus CRTD
CRT-D cardiac resynchronization therapy defibrillator, HF heart failure, ICD implantable cardioverter defibrillator, ICD-VR/DR single or dual lead implantable cardioverter defibrillator, KCCQ-12 12-item Kansas City Cardiomyopathy Questionnaire, SD standard deviation
KCCQ-12 score in 118 patients with primary prevention ICD due to heart failure stratified by age
| KCCQ-12 | 32–59 years (n = 10) | 60–69 years (n = 42) | 70–79 years (n = 42) | ≥ 80 years (n = 24) | Kruskal–Wallis test |
|---|---|---|---|---|---|
| Mean score | Mean score | Mean score | Mean score | ||
| Physical limitation | 75.8 ± 8.1 | 71.7 ± 24.9 | 67.5 ± 26.7 | 59.0 ± 27.5 | 0.164 |
| Symptom frequency | 80.1 ± 22.1 | 84.7 ± 19.7 | 75.7 ± 19.6 | 72.5 ± 23.8 | |
| Quality of life | 66.3 ± 28.3 | 72.9 ± 27.2 | 67.3 ± 24.4 | 69.8 ± 25.0 | 0.520 |
| Social limitation | 82.5 ± 22.7 | 72.0 ± 28.1 | 70.1 ± 25.1 | 69.1 ± 30.4 | 0.564 |
| Overall summary score | 75.6 ± 22.6 | 74.4 ± 22.9 | 69.6 ± 21.7 | 68.2 ± 23.0 | 0.402 |
Statistically significant p-values is given in bold
ICD implantable cardioverter defibrillator, KCCQ-12 12-item Kansas City Cardiomyopathy Questionnaire
Subgroup analyses of KCCQ-12 scores in 118 patients with primary prevention ICD due to heart failure
| KCCQ-12 | Atrial fibrillation | Appropriate therapy | Inappropriate shock | Complications | ||||
|---|---|---|---|---|---|---|---|---|
| Mean difference | Mean difference | Mean difference | Mean difference | |||||
| Physical limitation | − 10.0 | 0.051 | 9.9 | 0.238 | − 17.0 | 0.187 | 4.5 | 0.782 |
| Symptom frequency | − 12.0 | 2.4 | 0.946 | − 18.6 | 0.098 | − 0.4 | 0.864 | |
| Quality of life | − 8.2 | 0.119 | 0.7 | 0.795 | − 18.0 | 0.168 | 2.5 | 0.898 |
| Social limitation | − 13.5 | 3.9 | 0.958 | − 29.6 | 1.5 | 0.930 | ||
| Overall summary score | − 10.9 | 3.6 | 0.841 | − 21.8 | 2.0 | 0.925 | ||
Statistically significant p-values are given in bold
Positive mean difference indicates higher values
ICD implantable cardioverter defibrillator, KCCQ-12 12-item Kansas City Cardiomyopathy Questionnaire